Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Study of CSL222 (etranacogene dezaparvovec) in Adults with Hemophilia B and Pretreatment AAV5 Neutralizing Antibodies
KCT0010121Phase 3Not yet recruiting
- Sponsor
- CSL Limited
- Start
- Dec 2024
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Limited. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on KCT0010121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010121.